Goldman Sachs Upgrades Eli Lilly (LLY) to Neutral on New "Hope Trade"
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eli Lilly (LLY) Higher on Alzheimer Drug Hopes, Though Results Fail to Impress Analysts
October 9, 2012 11:39 AM EDTRecent studies of Eli Lilly's (NYSE: LLY) EXPEDITION in patients with mild Alzheimer's showed a statistically significant 34 percent slowing of cognitive decline versus placebo.
Analysts at MKM Partners said while the efficacy of Lilly's alzheimers drug was not overly impressive and longer-term... More
Goldman Sachs Downgrades Johnson & Johnson (JNJ) to Sell, Sees Limited Upside
October 9, 2012 7:25 AM EDTGoldman Sachs downgraded Johnson & Johnson (NYSE: JNJ) from Neutral to Sell with a price target of $72.00, saying they see limited upside.
The firm said they only see 7% upside for JNJ, versus 14% average upside for the rest of the group.
... More
Lilly (LLY) Updates on EXPEDITION in Alzheimer's; Slowing Observed in Pooled Analysis
October 8, 2012 1:18 PM EDTEli Lilly and Company (NYSE: LLY) announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease. This announcement follows the presentation of results from independent analyses of the EXPEDITION study data conducted by the Alzheimer's Disease Cooperative Study (ADCS), an academic research consortium, at the annual meeting of the American Neurological Association (ANA) by Rachelle Doody, M.D., Ph.D., professor of Neurology and the Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine. Dr. Doody is a member of the steering... More
